| Anaemic group N (45) | Non anaemic group N (69) | P value |
---|---|---|---|
Ageb | 42.9 ± 12. 9 | 42 ± 12.7 | 0.7 |
Gender (M/F)a | 31/14 | 47/22 | 0.93 |
Use of (EPO) pre transplanta | 12 (18.8%) | 52 (81.3%) | < 0.0001 |
Donor type a Living related | 38 (38.4%) | 61 (61.6%) | 0.54 |
Living unrelateda | 8 (53.3%) | 7 (46.7%) | Â |
History of rejectiona | 10 (76.9%) | 3 (23.1%) | 0.003 |
Use of Mycofenolate mofetila | 10 (32.3%) | 21 (67.7%) | 0.33 |
Use of Azathioprinea | 33 (41.2%) | 47 (58.8%) | 0.55 |
Use of Cyclosporinea | 22 (48.9%) | 23(51.1)% | 0.09 |
Use of Tacrolimusa | 21(32.3%) | 44 (67.7%) | 0.07 |
Use of ACEI/ARBa | 8(34.8%) | 15(65.2%) | 0.6 |
Presence of Co-Morbidities | 2(22.2%) | 7 (77.8) | 0.27 |
Time on dialysis (months)b | 12.9 ± 11.6 | 15.7 ± 13.8 | 0.26 |
Time since transplantation (months)b | 62.1 ± 51.5 | 40.5 ± 33.02 | 0.015 |
Donor age (years)b | 29.3 ± 7 | 28.5 ± 8 | 0.6 |
eGFR (ml/min/1.732 | 56.8 ± 20.7 | 97.7 ± 31.8 | < 0.0001 |